Preclinical characterization of a (S)-N-(4-Cyano-3-trifluoromethyl-phenyl)- 3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: A selective androgen receptor modulator for hormonal male contraception

Endocrinology

Volumn 150, Issue 1, 2009, Pages 385-395

  Jones, Amanda ^a   Chen, Jiyun ^a   Hwang, Dong Jin ^b   Miller, Duane D ^b,c   Dalton, James T ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c GTx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTRADIOL BENZOATE; FOLLITROPIN; LUTEINIZING HORMONE; N (4 CYANO 3 TRIFLUOROMETHYLPHENYL) 3 (3 FLUORO, 4 CHLOROPHENOXY) 2 HYDROXY 2 METHYL PROPANAMIDE; S 23; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BODY COMPOSITION; BODY FAT; BONE DENSITY; CASTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COPULATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EPIDIDYMIS; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL CONTRACEPTION; IN VITRO STUDY; LEAN BODY WEIGHT; LEVATOR ANI MUSCLE; LIBIDO; LOW DRUG DOSE; LUTEINIZING HORMONE BLOOD LEVEL; MALE; MALE INFERTILITY; MATING; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE MASS; NONHUMAN; PREGNANCY RATE; PRIORITY JOURNAL; PROSTATE; RAT; SEMINAL VESICLE; SEXUAL BEHAVIOR; SPERM; SPERMATOGENESIS; TESTIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ANILIDES; ANIMALS; BODY COMPOSITION; CONTRACEPTIVE AGENTS, MALE; ESTRADIOL; FEMALE; MALE; MUSCLE, SKELETAL; ORCHIECTOMY; ORGAN SIZE; PREGNANCY; PROSTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; SEMINAL VESICLES; SEXUAL BEHAVIOR, ANIMAL; SPERMATOGENESIS;

EID: 58149473439     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0674     Document Type: Article

References (51)

1. Hohlweg WaJ K 1932 Die hormonal-nervose regulierung der funktion des hypophysenvorderlappens. Klin Wochenschr 11:321
2. Dischreit J 1939 Wirkung des testikelhormonpraparates erugon auf den juvenilen rat-tenhoden, Klin Wochenschr 18:1493
3. Gaarenstroom JH 1939 Inhibition of the 'antimasculine effect' of oestrone by testosterone propionate. Acta Brev Neerl Physiol 9:134
4. Ludwig DJ 1950 The effect of androgen on spermatogenesis. Endocrinology 46:453
5. Nieschlag E, Nieschlag S, Behre HM 1998 Testosterone: action, deficiency, substitution. 2nd ed. New York: Springer
6. 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet 336:955-959
7. 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Feitil Steril 65:821-829
8. Amory JK, Page ST, Bremner WJ 2006 Drug insight: recent advances in male hormonal contraception. Nat Clin Pract Endocrinol Metab 2:32-41
9. Kamischke A, Nieschlag E 2004 Progress towards hormonal male contraception. Trends Pharmacol Sci 25:49-57
10. Yin D, Gao W, Kearbey JD, Xu H, Chung K, He Y, Marhefka CA, Veverka KA, Miller DD, Dalton JT 2003 Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 304:1334-1340
11. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT 2007 Selective androgen receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24:328-335
12. Chen J, Kim J, Dalton JT 2005 Discovery and therapeutic promise of selective androgen receptor modulators. Mol Interv 5:173-188
13. Chen J, Hwang DJ, Bohl CE, Miller DD, Dalton JT 2005 A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 312:546-553
14. Yin D, He Y, Perera MA, Hong SS, Marhefka C, Stourman N, Kirkovsky L, Miller DD, Dalton JT 2003 Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor. Mol Pharmacol 63:211-223
15. Kim J, Wu D, Hwang DJ, Miller DD, Dalton JT 2005 The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl- phenyl)-prop ionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. J Pharmacol Exp Ther 315:230-239
16. Lodder J, Baum MJ 1977 Facilitation of mounting behavior by dihydrotestosterone propionate in castrated estradiol benzoate-treated male rats following pudendectomy. Behav Biol 20:141-148
17. Baum MJ, Vreeburg JT 1973 Copulation in castrated male rats following combined treatment with estradiol and dihydrotestosterone. Science 182: 283-285
18. Feder HH 1971 The comparative actions of testosterone propionate and 5-androstan-17-ol-3-one propionate on the reproductive behaviour, physiology and morphology of male rats. J Endocrinol 51:241-252
19. McDonald P, Beyer C, Newton F, Brien B, Baker R, Tan HS, Sampson C, Kitching P, Greenhill R, Pritchard D 1970 Failure of 5a-dihydrotestosterone to initiate sexual behaviour in the castrated male rat. Nature 227:964-965
20. Jones ME, Boon WC, Proietto J, Simpson ER 2006 Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 17:55-64
21. Carani C, Rochira V, Faustini-Fustini M, Balestrieri A, Granata AR 1999 Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol (Oxf) 51:517-524
22. Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, Bohl C, Dalton JT, Miller DD 2004 Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J Med Chem 47:993-998
23. Chen J, Hwang DJ, Chung K, Bohl CE, Fisher SJ, Miller DD, Dalton JT 2005 In vitro and in vivo structure-activity relationships of novel androgen receptor ligands with multiple substituents in the B-ring. Endocrinology 146:5444-5454
24. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD 1998 Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4
25. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY 2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562-568
26. Anderson RA, Baird DT 2002 Male contraception. Endocr Rev 23:735-762
27. CaraniC, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER 1997 Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337:91-95
28. Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C 2004 Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 89:61-70
29. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698
30. Herrmann BL, Sailer B, Janssen OE, Gocke P, Bockisch A, Sperling H, Mann K, Broecker M 2002 Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endocrinol Metab 87:5476-5484
31. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A 2007 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 148:363-373
32. Oshima H, Wakabayashi K, Tamaoki BI 1967 The effect of synthetic estrogen upon the biosynthesis in vitro of androgen and luteinizing hormone in the rat. Biochim Biophys Acta 137:356-366
33. Verjans HL, de Jong FH, Cooke BA, van der Molen HJ, Eik-Nes KB 1974 Effect of oestradiol benzoate on pituitary and testis function in the normal adult male rat. Acta Endocrinol (Copenh) 77:636-642
34. Hislop MS, Ratanjee BD, Soule SG, Marais AD 1999 Effects of anabolicandrogenk steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur J Endocrinol 141:40-46
35. Watanobe H, Suda T 1999 A detailed study on the role of sex steroid milieu in determining plasma leptin concentrations in adult male and female rats. Biochem Biophys Res Commun 259:56-59
36. Pinilla L, Seoane LM, Gonzalez L, Carro E, Aguilar E, Casanueva FF, Dieguez C 1999 Regulation of serum leptin levels by gonadal function in rats. Eur J Endocrinol 140:468-473
37. Chen J, Guan N, Chung K, Miller DD, Dalton JT 2002 Modulation of hormonal biomarkers and target organ weights in vivo by selective androgen receptor modulators (SARMs). AAPS Pharm Sci 4:W5251 (Abstract)
38. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT 2004 Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 145:5420-5428
39. Turner TT, Jones CE, Howards SS, Ewing LL, Zegeye B, Gunsalus GL 1984 On the androgen microenvironment of maturing spermatozoa. Endocrinology 115:1925-1932
40. Jarow JP, Zirkin BR 2005 The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann NY Acad Sci 1061:208-220
41. Zirkin BR, Santulli R, Awoniyi CA, Ewing LL 1989 Maintenance of advanced spermatogenic cells in the adult rat testis: quantitative relationship to testosterone concentration within the testis. Endocrinology 124:3043-3049
42. Walsh PC, Swerdloff RS 1973 Biphasic effect of testosterone on spermatogenesis in the rat. Invest Urol 11:190-193
43. Awoniyi C, Santulli R, Chandrashekar V, Schanbacher BD, Zirkin BR 1989 Quantitative restoration of advanced spermatogenic cells in adult male rats made azoospermic by active immunization against LH or GnRH. Endocrinology 125:1303-1309
44. Awoniyi C, Zirkin BR, Chandrashekar V, Schlaff WD 1992 Exogenously administered testosterone maintains spermatogenesis quantitatively in adult rats actively immunized against GnRH. Endocrinology 130:3283-3288
45. Handelsman DJ, Wishart S, Conway AJ 2000 Oestradiol enliances testosteroneinduced suppression of human spermatogenesis. Hum Reprod 15:672-679
46. Awoniyi C, Sprando RL, Santulli RL, Chandrashekar V, Ewing LL, Zirkin BR 1990 Restoration of spermatogenesis by exogenously administered testosterone in rats made azoospermic by hypophysectomy or withdrawal of luteinizing hormone alone. Endocrinology 127:177-184
47. SaitoK, O'DonnellL, McLachlanRI, RobertsonDM2000 Spermiation failure is a major contributor to early spermatogenic suppression caused by hormone withdrawal in adult rats. Endocrinology 141:2779-2785
48. Beardsley A, O'Donnell L 2003 Characterization of normal spermiation and spermiation failure induced by hormone suppression in adult rats. Biol Reprod 68:1299-1307
49. Palacios A, McClure RD, Campfield A, Swerdloff RS 1981 Effect of testosterone enanthate on testis size. J Urol 126:46-48
50. Meachem SJ, Wreford NG, Stanton PG, Robertson DM, McLachlan RI 1998 Follicle-simulating hormone is required for the initial phase of spermatogenic restoration in adult rats following gonadotropin suppression. J Androl 19: 725-735
51. Ewing LL, Desjardins C, Irby DC, Robaire B 1977 Synergistic interaction of testosterone and oestradiol inhibits spermatogenesis in rats. Nature 269: 409-411